Chloroquine

Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021

Retrieved on: 
Monday, September 20, 2021
Biotechnology, FDA, AIDS, Health, Pharmaceutical, Other Science, Research, Public Relations, Investor Relations, Infectious Diseases, General Health, Hospitals, Communications, Science, Clinical Trials, Contraindication, ECMO, Subtypes of HIV, Marketing, Extracorporeal membrane oxygenation, Angioedema, Food and Drug Administration, Gilead, Review, Risk, 2021 Essex County Council election, Chloroquine, NDAS, HTE, AST, European Medicines Agency, Kidney failure, Boxed warning, Hospital, FDA, Patient, Hydroxychloroquine, Nausea, HIV/AIDS, Tachycardia, Hypertension, MAA, Bradycardia, AIDS, Dose, Rash, Perspiration, Anaphylaxis, COVID-19, Hypotension, Priority review, PDUFA, Breathe Me, Shivering, Effectiveness, Human, Maintenance, Fever, Hypoxia, ALT, History, Safety, Wheeze, EGFR, ULN, Lenacapavir, File, HIV, Hypersensitivity, Hepatitis, EMA, Birth control, Pharmaceutical industry, Medical device

As announced in August 2021, the MAA has been fully validated and is now under evaluation with the EMA.

Key Points: 
  • As announced in August 2021, the MAA has been fully validated and is now under evaluation with the EMA.
  • Veklury is contraindicated in patients with a history of clinically significant hypersensitivity reactions to Veklury or any of its components.
  • Veklury, Biktarvy, Descovy, Descovy for PrEP, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter ( @Gilead Sciences ) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

The Quinism Foundation Encourages Those Injured by Hydroxychloroquine and Related Quinoline Antimalarial Drugs to File Timely Claims for Government Compensation

Retrieved on: 
Friday, March 19, 2021
Chemical compounds, Quinolines, Chloroarenes, Organic compounds, Drugs, Quinism, Mefloquine, Hydroxychloroquine, Chloroquine, Emergency Use Authorization, Encephalopathy, Tafenoquine

[1] Hydroxychloroquine and chloroquine were subsequently approved by the U.S. Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA).

Key Points: 
  • [1] Hydroxychloroquine and chloroquine were subsequently approved by the U.S. Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA).
  • Dr. Nevin noted that more information on how to file a claim could be found at https://www.hrsa.gov/cicp/filing-benefits , or by visiting the website of The Quinism Foundation, at https://quinism.org .
  • The Quinism Foundation, founded in January 2018, in White River Junction, Vermont, promotes and supports education and research on quinism, the medical disorder caused by exposure to quinoline drugs, including tafenoquine, chloroquine, hydroxychloroquine, and mefloquine.
  • Neuropsychiatric Quinism: Chronic Encephalopathy Caused by Poisoning by Mefloquine and Related Quinoline Drugs.

Family Physician Reports Successful Treatment of COVID-19

Retrieved on: 
Tuesday, February 16, 2021
Chloroarenes, Quinolines, Hydroxychloroquine, Chloroquine, Clinical medicine, Health care, Health

Only about half a dozen of approximately 100 patients had to be hospitalized.

Key Points: 
  • Only about half a dozen of approximately 100 patients had to be hospitalized.
  • Dr. Smith learned of the use of hydroxychloroquine (HCQ) in nursing-home patients from a physician in Texas.
  • For more than 38 years he had prescribed HCQ for patients traveling to malarious regions, without difficulty.
  • Local physicians, a cardiologist and an ophthalmologist, told him they had seen no adverse effects from HCQ in their long careers.

Outlook on the Hydroxychloroquine Drugs Global Market to 2030 - Players Include Sanofi, Amneal Pharmaceuticals & Mylan Among Others

Retrieved on: 
Friday, February 12, 2021
Chloroarenes, Quinolines, Medical specialties, Hydroxychloroquine, Chloroquine, Health care, Medicine

Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018-2030

Key Points: 
  • Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018-2030
    6.3.
  • Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
    7.3.
  • Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Region
    8.3.
  • Middle East & Africa Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
    13.4.

Worldwide Hydroxychloroquine Drugs Industry to 2030 - by Disease Indication, Distribution Channel and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 11, 2021
Health, Pharmaceutical, Chloroarenes, Quinolines, Drugs, Medical specialties, Hydroxychloroquine, Health care, Compound annual growth rate, Chloroquine

The "Hydroxychloroquine Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydroxychloroquine Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The report provides the revenue of the global hydroxychloroquine drugs market for the period 2018-2030, considering 2019 as the base year and 2030 as the forecast year.
  • The report also provides the compound annual growth rate (CAGR %) of the global hydroxychloroquine drugs market from 2020 to 2030.
  • Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global hydroxychloroquine drugs market.

Lively Releases 2020 Data Showing Volatile Healthcare Spending Due to COVID-19

Retrieved on: 
Thursday, February 4, 2021
Professional services, Mental health, Health, Insurance, Human resources, General Health, Pharmaceutical, Chloroarenes, Quinolines, Medical specialties, Hydroxychloroquine, Chloroquine, HSA, Health care, Clinical medicine

Findings show that the COVID-19 pandemic had a serious impact on HSA spending in 2020.

Key Points: 
  • Findings show that the COVID-19 pandemic had a serious impact on HSA spending in 2020.
  • Even with so much fluctuation in the way customers used their HSAs, one element remained steady -- rising healthcare costs.
  • View the full release here: https://www.businesswire.com/news/home/20210204005102/en/
    2020 Lively HSA Spend Report (Graphic: Business Wire)
    Why did the spending shift?
  • In March, speculative treatments for COVID-19, such as chloroquine and hydroxychloroquine, caused a surge (+125%) in prescription spending across the country.

Dr. George Fareed and Colleagues Urge Early Outpatient Treatment for COVID-19

Retrieved on: 
Monday, January 11, 2021
Drugs, Medicine, Health sciences, Chloroarenes, Quinolines, Coronavirus disease, Occupational safety and health, Zoonoses, Ivermectin, Hydroxychloroquine, Chloroquine, Anticoagulant

Widely available treatments can reduce COVID-19 illness severity, hospitalization and mortality when used early.

Key Points: 
  • Widely available treatments can reduce COVID-19 illness severity, hospitalization and mortality when used early.
  • The outpatient therapies include combinations of widely available drugs and nutraceuticals (zinc, vitamin D, vitamin C, quercetin) as well as anti-infectives, steroids and anticoagulants if necessary.
  • The article notes that dozens of countries around the world are already using these drugs for early outpatient treatment of COVID-19, including some like Brazil and India which are widely distributing ivermectin and hydroxychloroquine in at-home treatment kits.
  • "Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)."

Worldwide Industry for Hydroxychloroquine to 2027 - Repurposing Hydroxychloroquine as an Anti-Cancer Drug Presents Opportunities

Retrieved on: 
Wednesday, January 6, 2021
Quinolines, Chloroarenes, Medical specialties, Hydroxychloroquine, Chloroquine, Antimalarial medication, Health care, Market, Clinical medicine

The global hydroxychloroquine market size was valued at $1.9 billion in 2019, and is anticipated to generate $4.6 billion by 2027.

Key Points: 
  • The global hydroxychloroquine market size was valued at $1.9 billion in 2019, and is anticipated to generate $4.6 billion by 2027.
  • Hydroxychloroquine, and anti-malarial drug, when combined with chloroquine has the potential to be the major game-changer in the medical history.
  • The hydroxychloroquine market forecast and estimations are based on factors impacting the market growth, in terms of value.
  • Profiles of leading players operating in the hydroxychloroquine market are provided to understand the global competitive scenario.

Global Hydroxychloroquine Market (2020 to 2027) - by Product Type, Distribution Channel and Disease - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 5, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Chloroarenes, Quinolines, Hydroxychloroquine, Chloroquine, Market, Clinical medicine, Health care, Health

The "Hydroxychloroquine Market by Product type, Distribution Channel, and Disease: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydroxychloroquine Market by Product type, Distribution Channel, and Disease: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global hydroxychloroquine market size was valued at $1.9 billion in 2019, and is anticipated to generate $4.6 billion by 2027.
  • The global hydroxychloroquine market is segmented into product type, distribution channel, disease, and region.
  • The hydroxychloroquine market forecast and estimations are based on factors impacting the market growth, in terms of value.

Jubilant Pharma Ltd. and Aavis Pharmaceuticals launch Hydroxychloroquine Sulfate tablets in the U.S. market

Retrieved on: 
Friday, November 6, 2020
Medical specialties, Clinical medicine, Medicine, Chloroarenes, Quinolines, Autoimmune diseases, Hydroxychloroquine, Chloroquine, Lupus, Rheumatoid arthritis

announce the launch of Hydroxychloroquine Sulfate tablets, 200 mg, a therapeutic equivalent version of Plaquenil (hydroxychloroquine sulfate) 200 mg in the U.S. market.

Key Points: 
  • announce the launch of Hydroxychloroquine Sulfate tablets, 200 mg, a therapeutic equivalent version of Plaquenil (hydroxychloroquine sulfate) 200 mg in the U.S. market.
  • The product will be distributed by Jubilant Cadista, a unit of Jubilant Pharma Ltd.
    Hydroxychloroquine Sulfate Tablets are indicated for the treatment of Malaria, Lupus Erythematosus and Rheumatoid Arthritis.
  • "We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S.through our marketing partner," stated Ashok Barot, Chairman, Aavis Pharmaceuticals.
  • For more information aboutAavis Pharmaceuticals, please visit www.aavispharma.com
    Senores Pharmaceuticals is an Ahmedabad, India based R&D partner and an affiliate of Aavis Pharmaceuticals.